Shaheer Khan

930 total citations
28 papers, 430 citations indexed

About

Shaheer Khan is a scholar working on Molecular Biology, Ophthalmology and Oncology. According to data from OpenAlex, Shaheer Khan has authored 28 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Ophthalmology and 12 papers in Oncology. Recurrent topics in Shaheer Khan's work include Ocular Oncology and Treatments (12 papers), Immunotherapy and Immune Responses (10 papers) and Ubiquitin and proteasome pathways (6 papers). Shaheer Khan is often cited by papers focused on Ocular Oncology and Treatments (12 papers), Immunotherapy and Immune Responses (10 papers) and Ubiquitin and proteasome pathways (6 papers). Shaheer Khan collaborates with scholars based in United States, Canada and United Kingdom. Shaheer Khan's co-authors include Richard D. Carvajal, Michael A. Postow, Jedd D. Wolchok, Christopher A. Barker, Preeti K. Parhar, Nancy Y. Lee, Yoshiya Yamada, Kathryn Beal, Mark Badeaux and Joseph M. Grimes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Shaheer Khan

27 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shaheer Khan United States 11 257 135 113 77 70 28 430
Hari Nadiminti United States 8 121 0.5× 100 0.7× 95 0.8× 11 0.1× 50 0.7× 15 358
Semih Doğan Türkiye 8 125 0.5× 68 0.5× 120 1.1× 25 0.3× 67 1.0× 15 360
Seema Sen India 11 66 0.3× 36 0.3× 112 1.0× 56 0.7× 22 0.3× 31 298
David Layfield United Kingdom 8 79 0.3× 70 0.5× 85 0.8× 61 0.8× 27 0.4× 16 380
Betül Çelik Türkiye 12 182 0.7× 37 0.3× 119 1.1× 10 0.1× 86 1.2× 52 481
Sima Torabian United States 9 134 0.5× 88 0.7× 257 2.3× 16 0.2× 41 0.6× 16 525
Dikan Wang China 9 218 0.8× 182 1.3× 111 1.0× 7 0.1× 54 0.8× 17 477
E Sun United States 6 121 0.5× 39 0.3× 96 0.8× 116 1.5× 13 0.2× 13 372
Aarti Bhatia United States 12 282 1.1× 55 0.4× 136 1.2× 11 0.1× 96 1.4× 33 580
Mirna Perusina Lanfranca United States 11 282 1.1× 265 2.0× 196 1.7× 5 0.1× 76 1.1× 13 569

Countries citing papers authored by Shaheer Khan

Since Specialization
Citations

This map shows the geographic impact of Shaheer Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaheer Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaheer Khan more than expected).

Fields of papers citing papers by Shaheer Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaheer Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaheer Khan. The network helps show where Shaheer Khan may publish in the future.

Co-authorship network of co-authors of Shaheer Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Shaheer Khan. A scholar is included among the top collaborators of Shaheer Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaheer Khan. Shaheer Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).
2.
Rapisuwon, Suthee, Richard D. Carvajal, George Ansstas, et al.. (2024). Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).. Journal of Clinical Oncology. 42(16_suppl). 9509–9509. 2 indexed citations
3.
Migden, Michael R., Wanxing Chai‐Ho, Gregory A. Daniels, et al.. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). SHILAP Revista de lepidopterología. A874–A874. 1 indexed citations
4.
Patel, Sapna P., Meredith McKean, Alexander N. Shoushtari, et al.. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology. 34. S677–S678. 2 indexed citations
5.
Sajan, Abin, Venkatesh Krishnasamy, Noor Ani Ahmad, et al.. (2023). Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases. Diagnostics. 13(11). 1836–1836. 7 indexed citations
6.
McKean, Meredith, Bartosz Chmielowski, Marcus O. Butler, et al.. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology. 34. S651–S651. 7 indexed citations
7.
Krishnasamy, Venkatesh, David Sperling, Joshua Weintraub, et al.. (2023). Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9590–9590. 1 indexed citations
8.
Wei, Alexander Z., Michael P. Manos, Jasmine H. Francis, et al.. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology. 12. 961517–961517. 6 indexed citations
9.
Khan, Shaheer, Sapna P. Patel, Alexander N. Shoushtari, et al.. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology. 12. 975643–975643. 5 indexed citations
10.
Khan, Shaheer, et al.. (2021). Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. Journal for ImmunoTherapy of Cancer. 9(10). e001219–e001219. 7 indexed citations
11.
Khan, Shaheer & Richard D. Carvajal. (2020). Novel Approaches to the Systemic Management of Uveal Melanoma. Current Oncology Reports. 22(10). 104–104. 11 indexed citations
12.
Grimes, Joseph M., Shaheer Khan, Mark Badeaux, et al.. (2020). Arginine depletion as a therapeutic approach for patients with COVID-19. International Journal of Infectious Diseases. 102. 566–570. 49 indexed citations
13.
Anderson, Michaela R., Bret Taback, Shaheer Khan, et al.. (2020). Case of Merkel cell carcinoma in a patient with pre-existing ILD. Journal for ImmunoTherapy of Cancer. 8(2). e001672–e001672. 1 indexed citations
14.
Trager, Megan H., Magdalena Jurkiewicz, Shaheer Khan, et al.. (2020). A Case Report of Papillary Digital Adenocarcinoma With BRAFV600E Mutation and Quantified Mutational Burden. American Journal of Dermatopathology. 43(1). 57–59. 10 indexed citations
15.
Khan, Shaheer & Ahmed Sawas. (2019). Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. Frontiers in Oncology. 9. 645–645. 12 indexed citations
16.
Khan, Shaheer & Richard D. Carvajal. (2019). Mucosal melanoma: current strategies and future directions. Expert Opinion on Orphan Drugs. 7(10). 427–434. 3 indexed citations
17.
Khan, Shaheer, et al.. (2017). Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma. The Cancer Journal. 23(1). 59–62. 8 indexed citations
18.
Barker, Christopher A., Michael A. Postow, Shaheer Khan, et al.. (2013). Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma. Cancer Immunology Research. 1(2). 92–98. 127 indexed citations
19.
Bello, Danielle M., Elizabeth Smyth, Daniel Pérez, et al.. (2013). Anal Versus Rectal Melanoma. Diseases of the Colon & Rectum. 56(2). 150–157. 47 indexed citations
20.
Khan, Shaheer, Margaret K. Callahan, Michael A. Postow, et al.. (2012). Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.. Journal of Clinical Oncology. 30(15_suppl). 8549–8549. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hari Nadiminti Breakdown of academic impact, for papers by Semih Doğan Breakdown of academic impact, for papers by Seema Sen Breakdown of academic impact, for papers by David Layfield Breakdown of academic impact, for papers by Betül Çelik Breakdown of academic impact, for papers by Sima Torabian Breakdown of academic impact, for papers by Dikan Wang Breakdown of academic impact, for papers by E Sun Breakdown of academic impact, for papers by Aarti Bhatia Breakdown of academic impact, for papers by Mirna Perusina Lanfranca
Rankless by CCL
2026